Postoperative minimal residual disease detection using tumor-informed circulating tumor DNA analysis in stage II–III gastric cancer: Updated analysis.
2026-05-15
Abstract
Background: Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) analysis may improve recurrence risk prediction and guide adjuvant chemotherapy (ACT) decisions in gastric cancer. This study evaluated the clinical utility of postoperative ctDNA MRD monitoring in stage II–III gastric cancer patients.
Methods: This sub-study of the EXODOX phase III trial analyzed postoperative ctDNA MRD using the CancerDetect assay developed by IMBdx. Tumor-informed personalized panels were generated for each patient, and blood samples were collected at multiple postoperative time points to assess MRD status.
Results: MRD positivity was more frequently observed in stage III disease and was strongly associated with increased recurrence risk and worse recurrence-free survival (RFS). Patients who achieved MRD clearance after adjuvant chemotherapy showed outcomes comparable to persistently MRD-negative patients, whereas persistent MRD positivity was associated with the poorest prognosis.
Conclusions: Postoperative ctDNA MRD detection effectively predicted recurrence in stage II–III gastric cancer. MRD dynamics during treatment may help guide adjuvant chemotherapy strategies and postoperative surveillance.